HE 2100

Drug Profile

HE 2100

Alternative Names: HE2100; NEUMUNE

Latest Information Update: 24 May 2011

Price : $50

At a glance

  • Originator Virginia Commonwealth University
  • Developer Armed Forces Radiobiology Research Institute
  • Class Androstenediols; Radioprotectives; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Neutropenia; Nosocomial infections; Radiation injuries

Most Recent Events

  • 20 Mar 2007 HE 2100 is available for licensing (http://www.holliseden.com)
  • 17 Mar 2007 Discontinued - Phase-I for Radiation injuries in USA (Injection)
  • 17 Mar 2007 Discontinued - Phase-I for Radiation injuries in Netherlands (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top